Join this session to hear two stories around public-private partnership in the Life Sciences and Health sector. Oncode Institute's Angus Livingstone, and hDMT Human Organ and Disease Model Technologies' Janny van der Eijnden-van Raaij, will be your hosts.

Part I
What Oncode stands for is better cancer treatment, faster. Excellence, both in the field of science and valorization, as well as collaboration is Oncode’s main character. Oncode presents a new model for excellence in science, inspired by international best practices and founded on the insights of leading oncology experts and the needs of society. In every aspect of its operation – from fundamental research to developing technologies to the teams of professionals it attracts – the Institute actively aims high. Oncode provides exceptional resources, helping accomplished scientists and top talents come together under the best possible conditions.

Oncode provides the funding and the tools to transfer technologies, enabling them to reach the marketplace effectively and affordably. A specialized team focused on transforming research results into real-world advances works to build an enterprise, establishing value and creating manifold partnerships.

About Oncode Institute
Oncode is an independent institute that brings 61 preeminent investigators totaling 850 scientists across 12 institutes with a single focus on cancer research. Our mission is translating scientific excellence to clinical benefit through collaboration.

Part II

Organ-on-Chip (OoC) technology is the game changer offering solutions for personalized and affordable healthcare as cutting-edge science, which goes beyond the frontiers of knowledge and requires multidisciplinary collaboration.

hDMT initiated and coordinated the H2020 FET Open project ORCHID (Organ-on-Chip In Development), which has laid the foundations of a European ecosystem on OoC technology by the establishment of the European Organ-on-Chip Society (EUROoCS). ORCHID has provided insight into the state-of-the-art, needs, challenges and impact of the OoC technology, which formed the basis for the development of the European OoC roadmap. As a follow-up to ORCHID, EUROoCS will facilitate implementation of the roadmap in an ongoing dialogue between developers, end users and regulators. A European Organ-on-Chip Infrastructure with testing, training and data centers is now being established under the umbrella of EUROoCS to accelerate adoption of OoC technology.

About hDMT, Organ-on-Chip Consortium in the Netherlands
The aim of hDMT, the Organ-on-Chip Consortium in The Netherlands, is to develop human Organ-on-Chip models that closely mimic the function of healthy and diseased human tissues and organs, and to enable their valorization and implementation. hDMT aims to make the models and data available to interested users by open access publication. hDMT is a growing pre-competitive, non-profit, technological research institute where internationally renowned scientists from 15 Dutch organizations (academic research centers, research institutes, University Medical Centers, and biotech companies) work together. They share knowledge, expertise and research facilities to develop Organs-on-Chips by integrating state-of-the-art human stem cell technologies and top level engineering with a wide variety of other disciplines.